Empagliflozin is a potent, selective, and competitive sodium-glucose co-transporter 2 (SGLT2) inhibitor used primarily in the management of type 2 diabetes mellitus (T2DM). It acts by reducing renal glucose reabsorption, leading to increased urinary glucose excretion (glucosuria) and a consequent reduction in plasma glucose levels. In the Indian context, it is a cornerstone of modern diabetes therapy, especially for patients with established cardiovascular or renal disease, as it has demonstrated significant cardiorenal protective benefits in landmark clinical trials (EMPA-REG OUTCOME).
Adult: The recommended starting dose is 10 mg once daily, taken in the morning, with or without food. The dose can be increased to 25 mg once daily for additional glycemic control or for cardiorenal protection.
Note: Swallow the tablet whole with a glass of water. Can be taken with or without food, preferably in the morning. Maintain adequate fluid intake to prevent volume depletion. Monitor blood glucose and renal function periodically.
Empagliflozin selectively and competitively inhibits the sodium-glucose co-transporter 2 (SGLT2) located in the proximal convoluted tubule of the nephron. SGLT2 is responsible for reabsorbing approximately 90% of the glucose filtered by the glomerulus. By inhibiting SGLT2, empagliflozin reduces the renal threshold for glucose (RTG), leading to increased excretion of glucose in the urine (glucosuria). This mechanism is independent of insulin secretion and beta-cell function.
Pregnancy: Not recommended during the second and third trimesters. Animal studies showed renal pelvic and tubule dilatation in offspring. There are no adequate and well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus. Indian guidelines advise switching to insulin.
Driving: Empagliflozin has no or negligible influence on the ability to drive and use machines. However, patients should be cautioned about symptoms of hypoglycemia (if on concomitant therapy), hypotension, or dizziness which may impair these abilities.
| Insulin or Insulin Secretagogues (Sulfonylureas, Meglitinides) | Increased risk of hypoglycemia. Dose reduction of insulin/secretagogue may be required. | Major |
| Loop Diuretics (Furosemide) | Additive diuretic effect; increased risk of volume depletion and hypotension. | Moderate |
| Lithium | Empagliflozin-induced diuresis may decrease lithium concentrations. Increased monitoring of lithium levels is recommended. | Moderate |
| Rifampicin | Induces UGT enzymes, potentially decreasing empagliflozin exposure. May reduce efficacy. | Moderate |
| Other SGLT2 Inhibitors | Additive pharmacodynamic effects; concomitant use is not recommended. | Major |